Navigation Links
Reforestation using exotic plants can disturb the fertility of tropical soils
Date:5/29/2008

In many regions of the world, the impact of human activity on the environment intensified considerably over the past century. The high world population growth rate and the expansion of areas given over to crop production associated with climatic changes (longer periods of drought, irregular rainfall patterns) induced by global warming, have contributed to the acceleration of desertification. According to World Soil Information (ISRIC) rate, in the space of 50 years, 12.8 million km2 of soils have thus experienced diminished fertility. With the aim of limiting such land impoverishment, which is hitting the intertropical and mediterranean zones particularly harshly, a range of reforestation programmes using rapid-growing forest species (such as eucalyptus, exotic pine or Australian acacias) was undertaken from the mid 1970s.

Establishment of bacterial and mycorrhizal symbioses provides these trees with the adaptation ability necessary for growth on virtually barren, mineral-deficient soil. Although no proof is needed as to their effectiveness for producing plant biomass in harsh environmental conditions and their utility as windbreaks to control erosion, there is little information on their potential impact on the genetic and functional biodiversity of the soil microorganisms. A research programme run since 2005 in Senegal and Burkina Faso by an IRD team and its partners1 yielded clues for understanding the influence of exotic plants on the structure and biodiversity of these communities of fungi and bacteria. In Burkina Faso, controlled experiments showed that the development of E. camaldulensis, the eucalyptus species most often planted in the world, outside its area of origin, significantly reduced the diversity of the mycorrhizal fungi communities essential for the healthy functioning of the ecosystem.

This negative effect was also found in the soil of a Senegalese plantation of Acacia holosericea where, scarcely a few months after it
'/>"/>

Contact: Gregory Flechet
fichesactu@paris.ird.fr
33-014-803-7607
Institut de Recherche Pour le Dveloppement
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
2. Using ground-penetrating radar to observe hidden underground water processes
3. Key to using local resources for biomass may include waste
4. A screening strategy using zebrafish targets genes that protect against hearing loss
5. The art of using science to inform ecosystem restoration in Puget Sound
6. Using DNA, scientists hunt for the roots of the modern potato
7. Paired microbes eliminate methane using sulfur pathway
8. Scientists find missing evolutionary link using tiny fungus crystal
9. Using carbon nanotubes to seek and destroy anthrax toxin and other harmful proteins
10. Using nanotechnology, UCLA researchers discover cancer cells feel much softer than normal cells
11. Using fMRI to study brain development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... February 9, 2010 Cellular imaging offers a wealth ... harnessing this technique to study biological systems is a ... Genome Research ( www.genome.org ), researchers have ... images to identify genetic interactions within biological networks, offering ... analysis. , For years, scientists have been peering through ...
(Date:2/8/2010)... The nation,s first fully integrated collaboration ... improve health and reduce healthcare spending has been ... .  The Full Yield rolls out in greater ... exclusive partnership with Harvard Pilgrim Health Care ... the U.S., and an inaugural partnership with ...
(Date:2/7/2010)... habits or behaviors, like cigarette smoking, may influence the ... HPV. , According to survey results on correlates ... vaccinate their daughters was not associated with one,s background ... certain behavioral factors of the parents. , Results of ... Cancer Epidemiology, Biomarkers & Prevention , a journal ...
Breaking Biology News(10 mins):Method of the future uses single-cell imaging to identify gene interactions 2The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 2The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 3The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 4The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 5More smokers than non-smokers accept HPV vaccination for their daughters 2More smokers than non-smokers accept HPV vaccination for their daughters 3NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 1NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 2NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 3NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 4NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 5NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 6Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 1Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 2Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 3Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 4Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 5Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 6Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 7Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 8Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 9Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 10Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 11Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 12Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 13Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 14Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 15Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 16Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 17Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 18Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 19Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 20Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 21Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 22Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 23Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 24Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 25Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 26Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 27Boston Scientific Announces Results for Second Quarter Ended June 30 2009 52158 28More Americans Have Cell Phones Than Dental Coverage 52153 1More Americans Have Cell Phones Than Dental Coverage 52153 2
... is a life-threatening disease caused by exposure to botulinum ... These neurotoxins are produced by Clostridium botulinum, a bacterium ... toxins bind to and enter neurons, interfering with nerve ... muscle fibers throughout the body. Poisoning with botulinum toxins ...
... outcome from traditional radiation and chemotherapy treatment for head ... a good prognosis with treatment of p53 tumor suppressor ... biomarker test for a gene-based drug. , Researchers at ... with advanced squamous cell carcinoma of the head and ...
... Library of Science (PLoS) announced today the creation ... access journal devoted to the world's most neglected ... ) will focus on the overlooked diseases that ... countries, including elephantiasis, river blindness, leprosy, hookworm, schistosomiasis, ...
Other Biology News:Abnormal overexpression of p53 is a predictive molecular biomarker 2Public Library of Science to launch new, open access journal on neglected tropical diseases 2Public Library of Science to launch new, open access journal on neglected tropical diseases 3
(Date:2/9/2010)... Belgium , February 9 /PRNewswire-FirstCall/ ... Examines the Potential of Microplasmin to Improve the ... Diseases ,, ThromboGenics NV ... discovery and development of innovative treatments for eye,disease, ... positive,microplasmin Phase II trial results, evaluating the product,s ...
(Date:2/8/2010)... MISSISSAUGA, ON , Feb. 8 /PRNewswire-FirstCall/ ... YM), today reported operational and financial results for ... December 31, 2009 . ,, "After rigorous evaluation ... merge Cytopia Limited., a clinical-stage, Melbourne -based ... quarter," said David Allan , Chairman & ...
(Date:2/8/2010)... CMED ), a leading China -based advanced in-vitro,diagnostic ("IVD") company, today announced that it will ... Conference Date ... Renshaw Annual March 7-9, 2010 The Regent ... ... Credit Suisse Asian March 22-26, ...
(Date:2/8/2010)... five months ahead of schedule ,, TSX Exchange Symbol: ... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today ... clinical study of its lead drug RVX-208. "The completion ... full 5 months ahead of our original schedule, is ... collaborators at the Cleveland Clinic. At this rate we ...
Breaking Biology Technology:ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4YM BioSciences reports second quarter 2010 operational and financial results 2YM BioSciences reports second quarter 2010 operational and financial results 3YM BioSciences reports second quarter 2010 operational and financial results 4YM BioSciences reports second quarter 2010 operational and financial results 5YM BioSciences reports second quarter 2010 operational and financial results 6YM BioSciences reports second quarter 2010 operational and financial results 7YM BioSciences reports second quarter 2010 operational and financial results 8YM BioSciences reports second quarter 2010 operational and financial results 9YM BioSciences reports second quarter 2010 operational and financial results 10YM BioSciences reports second quarter 2010 operational and financial results 11YM BioSciences reports second quarter 2010 operational and financial results 12China Medical Technologies to Participate Investor Conferences in March 2010 2Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 4
... July 17 Following intense,speculation in sections ... Daiichi Sankyo,Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") ... that the agreement,between Daiichi Sankyo, Ranbaxy and ... Ranbaxy, is binding and final, subject to,regulatory ...
... Supply Solutions(R),a focus area within SAFC(R), a ... today that the Company has launched a ... with their regulatory,requirement under the new European ... Authorization and restriction of Chemicals,(REACH) http://www.safcsupplysolutions.com/reach ...
... have combined the efforts of two kinds of bacteria to ... providing food for the other. According to an article in ... has an added bonus: leftover enzymes can be used to ... fuel cells that convert hydrogen into energy. , Hydrogen has ...
Other Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3Fuel from food waste: bacteria provide power 2
Assay Diluent Trial Pack, 4 x 100 mL...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: